The partnership aims to offer digital capabilities for pharmaceutical, biotech, medical device companies, contract research organisations (CROs), sites and investigators in order to enable quick commencement of clinical trials and boost digitalisation.
Under the multi-year alliance, Cognizant will develop managed services and solutions specific to solutions across Medidata’s platform such as randomisation and trial supply management.
Medidata chairman and CEO Tarek Sherif said: “This alliance exemplifies the power of Medidata’s technology combined with the expertise of the broadest and most advanced partner ecosystem, which we have built in life sciences.
“We are deepening our partnership with Cognizant to help customers around the globe fully realize the value of digital transformation.”
Medidata believes that the integration of Cognizant solutions with its platform will deliver clinical capabilities as-a-service for managing the growing complexities and global scale of clinical trials.
The company added that professional services from this partnership will provide life science companies with technology and expertise required to conduct trials that are becoming complex due to big data, artificial intelligence (AI) and focus on targeted therapies.
Cognizant senior vice-president and life sciences global head Bhaskar Sambasivan said: “Most life science companies have stitched together multiple legacy solutions and are in dire need for a clinical refresh.
“This partnership allows us to offer and manage the most comprehensive platform and suite of services for our clients so that they can focus on the science rather than operational complexities.”